Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Payables: 2015-2024

Historic Payables for Intellia Therapeutics (NTLA) over the last 10 years, with Dec 2024 value amounting to $14.6 million.

  • Intellia Therapeutics' Payables rose 0.87% to $13.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $50.0 million, marking a year-over-year decrease of 5.81%. This contributed to the annual value of $14.6 million for FY2024, which is 95.77% up from last year.
  • According to the latest figures from FY2024, Intellia Therapeutics' Payables is $14.6 million, which was up 95.77% from $7.5 million recorded in FY2023.
  • In the past 5 years, Intellia Therapeutics' Payables ranged from a high of $14.6 million in FY2024 and a low of $5.2 million during FY2022.
  • For the 3-year period, Intellia Therapeutics' Payables averaged around $9.1 million, with its median value being $7.5 million (2023).
  • As far as peak fluctuations go, Intellia Therapeutics' Payables skyrocketed by 165.41% in 2020, and later crashed by 46.61% in 2022.
  • Yearly analysis of 5 years shows Intellia Therapeutics' Payables stood at $10.5 million in 2020, then fell by 7.72% to $9.7 million in 2021, then crashed by 46.61% to $5.2 million in 2022, then spiked by 44.59% to $7.5 million in 2023, then surged by 95.77% to $14.6 million in 2024.